We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer's (PFE) Q3 earnings report on Tuesday, November 1 will give insight into its ability to sustain growth from its Covid-19 vaccines. The company's ability to beat earnings expectations may rely on the growth of other business units during the quarter.
BMY's YTD performance indicates the stock has been a viable hedge against inflation because people can ill afford to cut back on health-focused spending.
cancer: Archive
Buy this Medical Sector Pioneer Stock
by Shaun Pruitt
Gilead Sciences (GILD) is up roughly 20% since its Q3 release in October, let's take a look at what could continue propelling GILD stock.
GILDNegative Net Change AMGNNegative Net Change MRNANegative Net Change
cancer dividend-investing dividends immuno-therapy medical oncology-screening
How Markets Have Fared Under a Divided Congress
by Bryan Hayes
Markets typically applaud the 'certainty' that comes with a split Congress.
LLYNegative Net Change
cancer dividend-investing dividends earnings immuno-therapy inflation investing large-cap medical oncology-screening pharmaceuticals
Pfizer Earnings Preview: Growth & Diversification is Key
by Shaun Pruitt
Pfizer's (PFE) Q3 earnings report on Tuesday, November 1 will give insight into its ability to sustain growth from its Covid-19 vaccines. The company's ability to beat earnings expectations may rely on the growth of other business units during the quarter.
PFENegative Net Change JNJNegative Net Change ABBVNegative Net Change
cancer coronavirus dividend-investing dividends earnings hospitals medical oncology-screening pharmaceuticals vaccines
Should Investors Buy Bristol Myers Squibb Stock?
by Shaun Pruitt
BMY's YTD performance indicates the stock has been a viable hedge against inflation because people can ill afford to cut back on health-focused spending.
BMYNegative Net Change PFENegative Net Change
cancer dividends investing medical oncology-screening
Bull of the Day: Unum Group (UNM)
by Bryan Hayes
Unum Group has consistently enhanced shareholders' value through dividend hikes and share buybacks.
UNMPositive Net Change
cancer dividend-investing dividends earnings finance insurance investing
Bull of the Day: Illumina (ILMN)
by Kevin Cook
Leader in genomic sequencing still growing sales over 15% as lifescience labs crunch more genetic data
ILMNNegative Net Change NTRANegative Net Change
biotechnology cancer dna-sequencing genetic-testing genomics oncology-screening smart-health
Healthcare Outperformance May Signal Short-Term Market Bottom
by Bryan Hayes
This sector outperformance may be a sign the market is nearing a point of selling exhaustion.
JNJNegative Net Change XLVNegative Net Change
biotechnology biotechs cancer coronavirus dividend-investing dividends earnings etfs investing large-cap pharmaceuticals
BioPharma Giants Print Fresh All-Time Highs
by Bryan Hayes
The trend is our friend in this market, and these two biopharmaceutical stocks are trending exceptionally well.
REGNNegative Net Change BMYNegative Net Change
biotechnology cancer cell-therapy coronavirus earnings genetics hospitals immuno-therapy investing large-cap medical medical-devices pharmaceuticals
Bull of the Day: Pfizer Inc. (PFE)
by Bryan Hayes
With a dividend yield of 3% and a top Zacks VGM score of 'A', it's not hard to see why PFE is a top stock pick.
PFENegative Net Change
biotechnology biotechs cancer cell-therapy coronavirus dividend-investing dividends earnings genetics hospitals immuno-therapy investing large-cap medical oncology-screening pharmaceuticals vaccines
How to Select Stocks During Volatile Market Periods
by Bryan Hayes
How to Select Stocks During Volatile Market Periods
PFENegative Net Change ABBVNegative Net Change
biotechnology biotechs cancer cell-therapy coronavirus earnings investing large-cap medical pharmaceuticals smart-health
Follow The Leader: 3 Biopharma Stocks Displaying Relative Strength
by Bryan Hayes
3 Biopharma Stocks Displaying Relative Strength Heading Into 2022
REGNNegative Net Change GILDNegative Net Change CDMONegative Net Change
biotechnology biotechs cancer cell-therapy coronavirus earnings gene-therapy genetics hospitals immuno-therapy investing medical oncology-screening pharmaceuticals smart-health vaccines
The Death Rate Soared Last Year - But Not Why You Might Think
by Bryan Hayes
3 Funeral Services Stocks Hitting All-Time Highs
CSVNo Net Change SCIPositive Net Change HIPositive Net Change
cancer consumer-staples coronavirus earnings industrial-products investing medical
Bull of the Day: Mesa Laboratories (MLAB)
by Kevin Cook
Another solid quarter and growth ahead in genetic diagnostic services makes this small cap a buy
MLABNegative Net Change DHRNegative Net Change PACBNegative Net Change NVTANegative Net Change NTRANegative Net Change
cancer genetic-testing genomics medical smart-health
Bear of the Day: NeoGenomics (NEO)
by Kevin Cook
Emerging diagnostics provider is steadily growing sales and key M&A but ran into an EPS cliff
NEONegative Net Change EXASPositive Net Change NVTANegative Net Change NTRANegative Net Change GHNegative Net Change
biotechs cancer genetics genomics medical
Bull of the Day: Exact Sciences (EXAS)
by Kevin Cook
EPS surprises abound as Cologuard and Precision Oncology grow sales 20% into next year
EXASPositive Net Change ADPTNegative Net Change NVTANegative Net Change NTRANegative Net Change GHNegative Net Change
cancer coronavirus genetics genomics
Bear of the Day: Guardant Health (GH)
by Kevin Cook
Cancer detection innovator with liquid biopsy saw analysts slash estimates as R&D investment costs rise
GHNegative Net Change EXASPositive Net Change
cancer genetics genomics medical
Bear of the Day: CRISPR Therapeutics (CRSP)
by Kevin Cook
Gene editors got a big boost recently from sickle cell potential and Cathie Wood's thematic investing
CRSPNegative Net Change EDITNegative Net Change ARKKNegative Net Change NTLANegative Net Change ARKGNegative Net Change
biofuels cancer genetics genomics medical
Bull of the Day: Hologic (HOLX)
by Kevin Cook
This leader in women's health diagnostics is ramping high double-digit growth on COVID testing
QDELNegative Net Change HOLXNegative Net Change
cancer coronavirus medical
Healthcare & Biotech ETFs Digest GILD's Failure News: 5 Winners
by Sanghamitra Saha
Biotech and healthcare ETFs were pretty stable on Apr 23 despite the news that Gilead's Remdesivir failed to improve Covid-19 patients' condition.
GILDNegative Net Change IBBNegative Net Change CNCRNegative Net Change BBHNegative Net Change FBTNegative Net Change PTHNegative Net Change IHFNegative Net Change IHENegative Net Change XPHNegative Net Change SBIONegative Net Change XHSNegative Net Change PBENegative Net Change IDNANegative Net Change
biotechs cancer etfs